User profiles for Marco Marietta
 | Marco MariettaOspedale Policlinico - Modena Verified email at unimore.it Cited by 3948 |
Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis
BACKGROUND & AIMS: We performed a randomized controlled trial to evaluate the safety
and efficacy of enoxaparin, a low-molecular-weight heparin, in preventing portal vein …
and efficacy of enoxaparin, a low-molecular-weight heparin, in preventing portal vein …
[HTML][HTML] COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET)
The ongoing pandemic of Coronavirus disease 2019 (COVID-19) is severely challenging
healthcare systems all around the world, with the need to provide intensive care to a previously …
healthcare systems all around the world, with the need to provide intensive care to a previously …
Long‐term outcomes of patients with cerebral vein thrombosis: a multicenter study
…, D Coalizzo, R Benedetti, M Marietta… - … of thrombosis and …, 2012 - Wiley Online Library
Background: Little information is available on the long‐term clinical outcome of cerebral vein
thrombosis (CVT). Objectives and methods: In an international, retrospective cohort study, …
thrombosis (CVT). Objectives and methods: In an international, retrospective cohort study, …
Anticoagulant interventions in hospitalized patients with COVID‐19: A scoping review of randomized controlled trials and call for international collaboration
Introduction Coronavirus disease (COVID‐19) is associated with a high incidence of thrombosis
and mortality despite standard anticoagulant thromboprophylaxis. There is equipoise …
and mortality despite standard anticoagulant thromboprophylaxis. There is equipoise …
[HTML][HTML] COVID-19, coagulopathy and venous thromboembolism: more questions than answers
M Marietta, V Coluccio, M Luppi - Internal and emergency medicine, 2020 - Springer
The acute respiratory illnesses caused by severe acquired respiratory syndrome corona
Virus-2 (SARS-CoV-2) is a global health emergency, involving more than 8.6 million people …
Virus-2 (SARS-CoV-2) is a global health emergency, involving more than 8.6 million people …
[HTML][HTML] Safety of intravenous tranexamic acid in patients undergoing majororthopaedic surgery: a meta-analysis of randomised controlled trials
M Franchini, C Mengoli, M Marietta, G Marano… - Blood …, 2018 - ncbi.nlm.nih.gov
Among the various pharmacological options to decrease peri-operative bleeding, tranexamic
acid appears to be one of the most interesting. Several trials have consistently documented …
acid appears to be one of the most interesting. Several trials have consistently documented …
[HTML][HTML] Direct oral anticoagulants in patients with liver disease in the era of non-alcoholic fatty liver disease global epidemic: a narrative review
…, E Romagnoli, C Graziosi, A Lonardo, M Marietta… - Advances in …, 2020 - Springer
Atrial fibrillation (AF) and venous thromboembolism (VTE) are highly prevalent and relevant
healthcare issues. Direct oral anticoagulants (DOACs) are now the first-choice for …
healthcare issues. Direct oral anticoagulants (DOACs) are now the first-choice for …
[HTML][HTML] Risk and management of bleeding complications with direct oral anticoagulants in patients with atrial fibrillation and venous thromboembolism: a narrative …
…, A Athanasiou, M Di Girolamo, C Cappi, M Marietta… - Advances in …, 2023 - Springer
Atrial fibrillation (AF) and venous thromboembolism (VTE) are highly prevalent conditions
with a significant healthcare burden, and represent the main indications for anticoagulation. …
with a significant healthcare burden, and represent the main indications for anticoagulation. …
[HTML][HTML] Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus
M Napolitano, G Saccullo, M Marietta… - Blood …, 2019 - ncbi.nlm.nih.gov
Background Management of venous thromboembolism (VTE) in patients with haematologic
malignancies and thrombocytopenia is clinically challenging due to the related risks. No …
malignancies and thrombocytopenia is clinically challenging due to the related risks. No …
[HTML][HTML] Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe …
M Marietta, P Vandelli, P Mighali, R Vicini, V Coluccio… - Trials, 2020 - Springer
Objectives To assess whether high doses of Low Molecular Weight Heparin (LMWH) (ie
Enoxaparin 70 IU/kg twice daily) compared to standard prophylactic dose (ie, Enoxaparin 4000 …
Enoxaparin 70 IU/kg twice daily) compared to standard prophylactic dose (ie, Enoxaparin 4000 …